Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT00507871
Other study ID # 06-0033
Secondary ID
Status Completed
Phase N/A
First received July 26, 2007
Last updated December 2, 2009
Start date October 2007
Est. completion date January 2009

Study information

Verified date September 2007
Source Tufts University
Contact n/a
Is FDA regulated No
Health authority Uganda: Uganda National Council of Science and Technology
Study type Observational

Clinical Trial Summary

Cryptosporidium is an intestinal parasite that causes diarrhea in children and adults. In addition to infection of the stomach, this parasite can infect the respiratory system causing a cough and/or problems breathing. This study will enroll 480 children between the ages of 9 and 36 months who come to Mulago Hospital for treatment of diarrhea. Researchers believe a large number of children with diarrhea and cough will have the parasite present in their sputum (mucus coughed up). Researchers also believe that children who have respiratory tract cryptosporidiosis may have a cough, increased number of breaths per minute, and/or a lower oxygen level. Blood, stool, saliva, and sputum samples will be collected from all children in the study and tested for Cryptosporidium. Children too young to provide a sputum sample will have a tube placed to collect a mucus sample from the lungs. Study participation may be as short as 4 hours or as long as 2 days depending on each child's health.


Description:

Cryptosporidiosis is recognized as a major cause of diarrhea worldwide. In addition to infection of the gastrointestinal tract and associated fecal-oral transmission, there is evidence that Cryptosporidium can infect the respiratory tract. Of particular interest are numerous reports indicating that respiratory symptoms occur with considerable frequency in subjects with intestinal cryptosporidiosis although the etiology of the respiratory symptoms was never investigated. The association between respiratory symptoms and intestinal cryptosporidiosis is particularly strong in children with questionable nutritional status. This study will evaluate the prevalence and clinical presentation of respiratory cryptosporidiosis among children with diarrhea in Mulago Hospital, Kampala, Uganda. The study will screen approximately 1536 children aged 9-36 months who present to the Acute Care Unit of Mulago Hospital in Kampala, Uganda, with acute or persistent diarrhea. Based on the results of fecal testing, 480 children will be actively selected to undergo further sample collection in 2 groups. Group 1 will be comprised of children with Cryptosporidium-positive stools, approximately 50% of whom are expected to have cough (n=384). Group 2 will be comprised of children with Cryptosporidium-negative stools and cough (n=96). The primary objectives of the study are: to establish the prevalence of cough in children with diarrhea due to Cryptosporidium infection; to establish the prevalence of respiratory tract cryptosporidiosis in children with diarrhea due to Cryptosporidium infection; to establish the prevalence of respiratory tract cryptosporidiosis in children with diarrhea due to other causes; and to determine whether respiratory Cryptosporidium infection in children is associated with increased respiratory rates and decreased oxygen saturation levels. To address these objectives, the study will focus on whether Cryptosporidium oocysts can be recovered from induced sputum of subjects who have acute or persistent diarrhea and are concurrently experiencing a cough or unexplained tachypnea or hypoxemia. The primary clinical measures include: duration of diarrhea (days); presence and duration of cough (days); respiratory rate at presentation and if dehydrated, after rehydration; oxygen saturation (as measured by pulse oximetry) at presentation; and oxygen therapy requirement and oxygen saturation after 30 minutes of oxygen therapy if initial saturation is <92%. Primary parasitological measures include: presence or absence of Cryptosporidium in stool (as detected by modified acid fast staining and PCR); presence or absence of Cryptosporidium in sputum (as detected by PCR); and presence or absence of Cryptosporidium in saliva (as detected by PCR). Secondary clinical measures include: HIV status (determined by voluntary HIV testing via enzyme-linked immunosorbent assay + reverse transcriptase PCR in children aged less than 18 months); CD4+ counts/percentages (as measured by flow cytometry in children tested for HIV); concurrent respiratory infection (as determined by processing of sputum for routine bacterial pathogens, tuberculosis and pneumocystis jirovecii pneumonia; anemia (determined by hemoglobin measurement from complete blood count); and nutritional status (as determined from the weight-for-age score, height-for-age score, weight-for-height score, head circumference, and mid upper arm circumference). Secondary parasitological measurements include: species of Cryptosporidium in stool, in sputum, and in saliva (as determined by restriction fragment length polymorphism). Subject participation duration in the study is dependent on the health status of the child at admission and the extent of clinical care required. In uncomplicated cases, subject duration may be as short as 4 hours. In subjects requiring extensive clinical care subject duration may extend to 2 days.


Recruitment information / eligibility

Status Completed
Enrollment 480
Est. completion date January 2009
Est. primary completion date January 2009
Accepts healthy volunteers No
Gender Both
Age group 9 Months to 36 Months
Eligibility Inclusion Criteria:

- Male and female children aged 9-36 months at the time of enrollment

- Presence of acute or persistent diarrhea (diarrhea defined as 3 or more loose stool in the previous 24 hours AND not considered normal for that child if the child is exclusively breast fed OR any number of bloody stools in the previous 24 hours; less than or equal to 14 days duration for acute diarrhea; >14 days duration for persistent diarrhea)

- Child's parent/guardian speaks English or Luganda

- Parent/guardian provides full and free informed consent for child to participate in study

Exclusion Criteria:

- Unknown age

- Known cardiac, CNS, metabolic or endocrine disorders

- Moribund children

- Children with recent history of choking or sudden onset of symptoms with suspected foreign body inhalation

Study Design

Time Perspective: Prospective


Related Conditions & MeSH terms


Locations

Country Name City State
Uganda Makerere University Medical School Kampala

Sponsors (2)

Lead Sponsor Collaborator
Tufts University National Institute of Allergy and Infectious Diseases (NIAID)

Country where clinical trial is conducted

Uganda, 

See also
  Status Clinical Trial Phase
Terminated NCT00057486 - Interleukin 12 (IL-12) for the Treatment of Cryptosporidiosis in AIDS Patients Phase 1/Phase 2
Terminated NCT00001162 - Parasitic Infections of the Gastrointestinal Tract N/A
Recruiting NCT05208970 - Cryptosporidium Species in Sohag Governorate
Recruiting NCT04332705 - Cryptosporidium Infection and Human Colorectal Cancer
Active, not recruiting NCT02764918 - Cryptosporidiosis and Enteropathogens in Bangladesh
Not yet recruiting NCT01695304 - Trial of Ceramic Water Filters to Reduce Cryptosporidium Infection in Kenya N/A
Terminated NCT00004986 - Safety and Effectiveness of Nitazoxanide for the Treatment of Cryptosporidiosis in AIDS Patients Phase 3
Completed NCT04103216 - Treatment of Cryptosporidiosis N/A
Terminated NCT03341767 - A Phase 2A Evaluation of the Safety, Tolerability, Pharmacokinetics, Efficacy of Clofazimine (CFZ) in Cryptosporidiosis Phase 2
Completed NCT01699841 - Breast Milk Composition and HIV-exposed/Unexposed Early Infant Growth and Infectious Disease Events N/A
Active, not recruiting NCT00002158 - A Study to Evaluate the Use of Nitazoxanide to Treat Cryptosporidiosis N/A
Completed NCT00002248 - A Randomized, Multicenter, Double-Blind, Parallel-Group, Placebo-Controlled Trial of the Efficacy and Safety of Bovine Anti-Cryptosporidium Immunoglobulin (BACI) in the Treatment of Cryptosporidium Enteritis in AIDS Patients Phase 1
Completed NCT00002062 - Open-Label "Compassionate" Use Study of Spiramycin for the Treatment of Diarrhea Due to Chronic Cryptosporidiosis in Immunocompromised Patients N/A
Completed NCT00002278 - A 28-Day Study of Diclazuril in the Treatment of Cryptosporidiosis in Patients With AIDS N/A
Completed NCT00055107 - Nitazoxanide for the Treatment of Chronic Diarrhea in HIV Infected Children Phase 1/Phase 2
Completed NCT00002082 - Azithromycin in the Treatment of Cryptosporidiosis in Patients With Acquired Immune Deficiency Syndrome (AIDS): A Randomized, Multi-Center, Placebo-Controlled, Double-Blind Study N/A
Completed NCT00002264 - The Effectiveness of Cow's Milk Immune Globulin in the Treatment of AIDS-Related Diarrhea N/A
Completed NCT00001018 - A Study of Letrazuril in the Treatment of AIDS-Related Diarrhea Phase 1
Terminated NCT00001128 - Treatment of Chronic Cryptosporidiosis in AIDS Patients N/A
Completed NCT00000771 - A Double-Blind, Placebo-Controlled Trial of Paromomycin for Treatment of Cryptosporidiosis in Patients With Advanced HIV Disease and CD4 Counts Under 150 Cells/mm3 Phase 2